Home > Boards > US OTC > Biotechs > NanoLogix, Inc. (NNLX)

Company updates

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
GroypLogix Member Profile
 
Followed By 14
Posts 2,597
Boards Moderated 1
Alias Born 01/12/07
160x600 placeholder
GroypLogix   Monday, 12/16/19 03:47:27 PM
Re: None
Post # of 10037 
Company updates


Dec. 16, 2019

NanoLogix Update on Phase One PreTest Development

NanoLogix is pleased to provide an update on the development of a  Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021. 

The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx

It is also available on our website at: http://nanologix.com/

Further updates will occur as warranted.


Oct. 14, 2019

NanoLogix Provides Update on Development

NanoLogix is pleased to provide this brief update on the development on the N-Assay Bacteria Diagnostic Screening/Pretest. The development work in the UK by a company with Global operations began on October 1st and is in the first of four phases that will carry through to patient studies in Houston planned for 2020. This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI (Urinary tract infections) projected for 2021. 

The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.

In step with the development plans, NanoLogix has requested assistance from the Youngstown State University's Career Center in locating and hiring two laboratory personnel for our Ohio Lab. These personnel will configure the N-Assay Diagnostic tests to conform with the results and efforts of the UK development company.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx

It is also available on our website at: http://nanologix.com/

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

Further updates will occur as warranted.


Aug. 21, 2019

NanoLogix Seeks $3 Million For Expansion and Development – Offers Net-Revenue Share of N-Assay Bacteria Diagnostic

NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx

It is also available on our website at: http://nanologix.com/

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

Further updates will occur as warranted.


Apr. 30, 2019

Enhanced Update on N-Assay – Overview and Potential in Multi-billion Dollar Diagnostics Market

NanoLogix has updated an important PowerPoint Presentation on the N-Assay Bacteria Diagnostic. The update includes additional information on Upper Repiratory Infections (URI), general Sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information  on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx

It is also viewable on our website at: http://nanologix.com/

The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

Further updates will occur as warranted.

 
Apr. 2, 2019

Update on N-Assay – Overview and Potential in Multi-billion Diagnostics Market
 
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms. 
 
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/

The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
 
Further updates will occur as warranted.
 
 
Jan. 16, 2019
 
Update on N-Assay Pretest Development
 
NIH Grant Application Submitted for Pre-test Development Study 
 
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recommendation from noted medical authorities written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
 
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge. 
 
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
 
The current focus of this NIH grant application is on Group B Streptococcus (GBS). We are currently discussing Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
 
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
 
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
 
Further updates will occur as warranted.
 
 
Dec. 19, 2018

Nigeria FlatPack Patent Granted
 
NanoLogix is extremely pleased to have received notification of grant from the patent firm of Spoor and Fisher of the acceptance and grant in Nigeria for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Nigeria patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, Mexico, and the European Union.
 
Efforts are ongoing for both license and/or sale of the FlatPack rights in countries outside of the USA, with varied levels of interest from manufacturers.
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
For reference, this patent took nearly 7-1/2 years to be issued from the date or Patent Cooperation Treaty (PCT) filing.
 
 
Oct. 26, 2018

N-Assay Summary for upcoming NanoLogix Website
 
New write up that will be posted on our new website soon for our patented diagnostic. Comments and interest welcomed: 

Nanologix' N-Assay offers an innovative solutions to a major problem that has plagued physicians over the years.

In medicine, nothing gets a clinician's attention like sepsis. When one has seen a patient who had previously been doing just fine suddenly take a turn for the worse, management decisions must be made without hesitation. In the case of a septic patient, seconds mean the difference between life and death, and minutes are a luxury that neither the clinician nor the patient may afford. The post-operative patient, the post-partum patient, the ICU patient... any patient is at risk of encountering a virulent pathogen in the hospital, and without an astute clinician ready to respond, serious consequences will occur. It's not surprising that the Infectious Disease Society of America estimates just this year that treating infections cost 21 to 34 billion dollars annually, in the US alone.

Clinicians currently have two techniques at their disposal when treating a presumed infection -culture, and PCR. The traditional technique of culture is labor intensive, requires laboratory-trained personnel, and correctly obtained, viable material. Although this method is relatively inexpensive, it is incredibly time-consuming. Patients often find it hard to believe that obtaining a culture result and antibiotic sensitivity profile may take 5 days! While the clinician is waiting for the results, they are throwing everything they've got at the possible infection. This is truly an empiric approach, and here it pays to have an experienced clinician by your side.

The alternative method, PCR, is much faster, much more sensitive, but also much more expensive. This newer technique also costs a great deal more, and requires highly trained personnel to operate the devices. These machines also incur a large capital investment by the hospital, as well as annual maintenance. In spite of the strengths of PCR, it also has weaknesses -it is unable to differentiate the difference between live/dead bacteria, and can not provide estimates relating to the degree of the inoculum. This information is essential for the clinician in directing targeted therapy, so again, they are ultimately forced to rely on their experience when treating the patient.

Regardless of one's opinion as to whether culture or PCR is the better option, the data over the last few decades shows the depressing truth -neither option is offering us any real advantage. This is made clear when one looks at the development of antibiotic resistance. These bugs have continued to grow and evolve, and a few years ago, a gonorrhea "super-bug" was isolated -showing resistance to every antibiotic available. We are clearly losing the war against these single-cell enemies!

In answer to this major problem, we have developed and patented an approach that takes all of the advantages of both culture and PCR (specificity, sensitivity, speed, and accuracy as well as ease of use), and none of the disadvantages. This technique, termed the N-Assay, is an antibody-based assay that targets potentially any bacterial pathogen (and has also been seen to detect yeast), in as little as 30 minutes. In addition, when incubated for 6 hours, this test not only provides a bacterial identification, but also allows the clinician to determine which antibiotic will work in treating the infection. This test will dramatically shorten the amount of time required for a clinician to wait when treating the ill patient, and should ultimately save billions in healthcare spending. Furthermore, by more accurately targeting the right bacterium with the correct antibiotic, we should drastically reduce the incidence in antimicrobial resistance.

We have already used a pilot version of this test in detecting group B streptococcus colonization in pregnant women, and have won an award at an OB GYN conference when presenting our data. The clinicians see that this test has tremendous potential, and are eager for it to be available, as they simply need better methods to more accurate diagnose infection. With the right resources, we will be able to expand this test to additional bacterial pathogens, such as E. coli, Enterococcus, MRSA, and any other clinically relevant pathogen. 
 
 
Sept. 7, 2018 
 
Notice of Upcoming NanoLogix Website Revision  
 
Request For Confirmation of Continuing Interest From Newsletter Subscribers
 
NanoLogix is pleased to announce the Company website will be extensively revised and updated during September and October. The Company requests that those Newsletter Subscribers who are interested in continuing to receive updates of NanoLogix news through our iContact news service to send a confirmation email to: info@nanologix.com  
 
This revision will enable the Company to significantly improve the website, providing the ability to respond rapidly to business events and to quickly furnish business,  technology, and hospital study updates.
 
 
Aug. 20, 2018
 
NanoLogix Attends Series of Meetings In Houston
 
Preparation for Pre-test Development Study
 
NanoLogix is pleased to announce their attendance at a series of meetings in Houston with Drs. Sebastian and Jonathan Faro and the CEO of a California-based Biotechnology firm. The purpose of the meetings was for coordinating forces for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic. The meetings dealt with organization and staffing of a research study at two major Houston hospitals, funded from both Federal Grants and a raise of investment capital, and the specific personnel required for the successful execution of the study. The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge. 
 
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
 
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
 
Dr. Jonathan Faro, PhD, MD stated: "These are incredibly exciting times for Nanologix. Seeing this study begin to crystallize has been invigorating, and it's wonderful to see other health care providers share an interest in our test, which is the leading diagnostic assay in bacterial identification and determination of antibiotic susceptibility. When speaking with nurses and other doctors, it's extraordinary to see their enthusiasm for the test --- we have found the right home for a study of this magnitude."
 
 
July 16, 2018
 
NanoLogix Welcomes Dr. Jonathan Faro to Board of Directors
 
Jonathan Faro, PhD, MD, joins as Director of Medical Development
 
NanoLogix is pleased to announce the addition of Jonathan Faro, PhD, MD to the Company's Board of Directors. Dr. Faro is the co-inventor of the N-Assay modified ELISA bacteria-detection and identification technology and primary author of a number of published peer-reviewed research papers on the technology.
 
Dr. Faro's statement:
 
I am very excited to have joined the Board of Directors at NanoLogix, Inc. As the Director for Medical Development, I will serve a direct role in advocating for the goals of the company, and plan to work alongside the CEO and other boardmembers to further development of the N-Assay. With their support, I have several goals that I aim to achieve. First and foremost, several studies need to be initiated. In addition to a large, multi-site study involving both private and academic centers, we will work on establishing multiple small-scale studies. Each of these will focus on the unique strengths of the N-Assay, so that clinicians will see that the assay is superior to anything currently on the market. We will focus on a four-pronged approach:
 
A) Speed of pathogen identification, providing clinicians with an accurate result far faster than that of culture, 
 
B) Determination of antimicrobial resistance, so that clinicians may target their approach quickly, and begin seeing results faster than with any other technology on the market. 
 
C) Offer clinicians novel approaches in treating infectious diseases, so that we stop the continued development of antimicrobial resistance.
 
D) Offer cheaper tests that do not increase the burden on national and international healthcare resources.
 
This final goal will have the benefit of taking NanoLogix not just through the US market, but will allow it to gain steady footing in the global market, which is necessary in order to truly help in limiting the spread of antimicrobial resistance, which currently claims approximately 700,000 lives per year. Although each of these goals will require considerable time, effort, and financial support, we have already begun the process of building in-roads with multiple well-respected clinical collaborators. These next several months certainly will be very exciting times for both myself and for NanoLogix!
 
 
Apr. 19, 2018
 
Update On Petri FlatPack International Patent Status
 
Pursuant to NanoLogix' International Patent Offering
 
NanoLogix is pleased to announce payment yesterday (18 April 2018) of annuities for the FlatPack petri plate extended-life packaging patent in the EU and other granting countries. These annuity payments were made possible through a long time shareholder's efforts and the resulting receipt of funds by the Company from a new investor. The importance of the annuity payments cannot be overstated for the development of Nanologix --- sale and/or licensing of the FlatPack Patents internationally is projected to provide funding for the Company's expansion of agar-filled petri plate production in the USA and to complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
 
Without the potential to monetize the international patent assets the Company's development would depend upon domestic organic growth only, a process that while steady, would not meet NanoLogix' needs for rapid expansion.
 
 
Apr. 11, 2018
 
Further European Patent Office Information on FlatPack Patent for Sale and Licensing
 
International Patent Offering
 
NanoLogix is pleased to announce receipt today (dated 11 April 2018) of notice from the European Patent Office (EPO) of the expiration of the nine-month opposition filing period for the FlatPack petri plate extended-life packaging patent (European Patent No. 2699491). The reason for this update from Nanologix is to inform all interested parties that out of the fourteen signatory countries chosen and paid for the registration and validation of the Flatpack Patent in early September 2017, prior to the receipt of this notice from the EPO, of the signatory states for the EU Patent treaty only the three non-EU member states of Sweden, Croatia, and Turkey had published notice of validation of the Flatpack patent in their respective patent bulletins. 
 
Notice from the EPO states: "The entry in the Register of European Patents will be automatically generated by the electronic data processing system".
 
Further information from this notice: "This European patent has become wholly equivalent to a bundle of national patents in the designated states in which the patent was validated".
 
The publication in the EU Patent Registry is the essential and final step to enable NanoLogix to offer a fully registered and validated patent in the EU for license and/or sale. This step is in accordance with the Company's stated goal of using receipts from those efforts to fund expansion of agar-filled petri plate production in the US and complete development and pursue marketing of both the N-Assay modified ELISA rapid bacteria diagnostic test and its associated Pre-test.
 
The Company is currently seeking to raise $30,000 for the April payment of the international annuities for the issued FlatPack patents and pending applications in the following countries:
 
Issued: China, New Zealand, Chile, Mexico, South Africa, UK, Germany, Sweden, France, Spain, Italy, Switzerland, Serbia, Croatia, Turkey, Denmark, Ireland, Poland, and the Netherlands.
 
Pending:  Brazil, Canada


Nov. 27, 2017
 
Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application
 
International Patent Offering
 
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
 
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
 
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
 
Central Association of Obstetricians and Gynecologists
 
Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:
 

 
NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.
 
National Science Foundation Grant Application
 
NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:
 
https://seedfund.nsf.gov
 
While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.


Sept. 1, 2017
 
Tropical Storm Harvey and FlatPack Update
 
NanoLogix is donating 1,000 specialized petri plates in 100 FlatPacks of ten plates each to a major hospital in Houston for their use in testing for contamination caused by flooding in their facility. As electrical power loss has been significant in the area a major determining factor in the selection by hospital staff was the ability of our FlatPack petri plates to be stored at room temperature for extended periods, while other manufacturers' products must be refrigerated. This highlights just one of the many qualities of the argon-flushed FlatPack vacuum packaging for petri plates.
 
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
 
Aug. 31, 2017
 
EU, Hong Kong & PRC FlatPack Update
 
NanoLogix is pleased to announce initial interest from both the EU and PRC areas in the offer for sale of the Flatpack patents for those areas.
 
To maintain rights for the near future in various EU patent agreement signatory countries while awaiting firm commitments for sale, we are paying the registration fees for the FlatPack patent in the following 14 countries:
 
Croatia
Denmark
France
Germany
Italy
Ireland
The Netherlands
Poland
Serbia
Spain
Sweden
Switzerland/Lichtenstein
Turkey
The UK
 
The fees for the 14 countries are approximately $30,000 USD.
 
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.  
 
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+  types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
 
 
Aug. 2, 2017
 
NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego
 
 The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:
 

 
The significance of the results shown in the presentation cannot be overstated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.
 
Dr.Jonathan Faro, PhD, MD, tweeted the following two messages yesterday: 
 
"Excited to be at AACC 2017! Over 20,000 registrants and lots of great exhibits!"
 
"Having a great time at AACC 2017! Getting a lot out of the exhibits. Lots of exciting new technology, but nothing close to the N-Assay!"
 
You may follow this link to the AACC information website:
 
https://www.aacc.org/meetings-and-events/2017-annual-meeting
 
 
July 12, 2017
 
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
 
HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
 
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
 
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
 
 
July 5, 2017
 
Mexico FlatPack Patent Granted
 
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
 
 
June 22, 2017
 
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
 
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.  
 
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+  types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
 
 
June 8, 2017
 
EU & Hong Kong FlatPack Patent Issued
 
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
 
A PDF of the issued patent may be viewed here: 
 
http://www.freepatentsonline.com/EP2699491.pdf
 
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
 
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
 
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
 
For reference: The patent process from the date of filing to issuance took five years and two months.
 
 
June 5, 2017
 
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
 
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
 
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
 
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
 
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories. 
 
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity. 
 
Two published examples of the N-Assay and its performance can be accessed through the following links:
 
https://www.hindawi.com/journals/idog/2016/5293034/
 
http://nanologix.com/news/poster-e-coli-0157.pdf
 
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
 
 
June 2, 2017
 
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
 
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
 
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
 
http://nanologix.com/news/poster-e-coli-0157.pdf
 
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
 
 
June 1, 2017
 
NanoLogix TB Detection Technology Use on Africa Project Increases
      
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies. 
 
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
 
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
 
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
 
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."  
 
 
May 19, 2017
 
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
 
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
 
Novel Immunoassay for E coli O157:H7
 
Researchers: Classified until June 2017
 
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
 
Methods: N-ASSAY
 
Methods Details Classified until June 2017
 
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
 
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
 
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
 
 
May 8, 2017
 
Additional TB Test Kits ordered for Third World Gates Foundation Project
 
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.  
 
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly. 
 
 The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link: 
 
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html ;
 
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.   
 
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile. 
 
 
May 4, 2017
 
TB test Kits for use in Third World Gates Foundation Project
 
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies. 
 
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces. 
 
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs. 
 
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses. 
 
...and now we've sold TB diagnostics for use on a project funded by whom...? 
 
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper. 
 
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area. 
 
 
Apr. 28, 2017
 
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
 
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session. 
 
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates. 
 
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. 
 
The published research results may be accessed through this link: 
 
http://dx.doi.org/10.1155/2016/5293034
 
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method. 
 
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link: 
 
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo ;
 
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here: 
 
https://www.asm.org/index.php/asm-microbe-2017
 
 
Apr. 4, 2017
 
NanoLogix has shipped TB test Kits for use in Third World Project
 
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
 
 
Mar. 16, 2017
 
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
 
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
 
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
 
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
 
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
 
 
Mar. 2, 2017
 
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
 
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
 
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
 
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
 
 
Jan. 9, 2017
 
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
 
The N-Assay takes its place on our FDA medical device listing:
 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
 
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. 
 
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
 
 
Dec. 20, 2016
 
NanoLogix is pleased to announce the following Update:
 
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
 
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
 
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
 
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
 
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
 
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name. 
 
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
 
 
Dec. 6, 2016
 
NanoLogix is pleased to announce the following Update:
 
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
 
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
 
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
 
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
 
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
 
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
 
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
 
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
 
 
------------------------------------------------------------------------------------------------------------------------------
 
 
Updates are available by signing up for eNews on the company's homepage at nanologix.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist